Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
企業コードDARE
会社名Dare Bioscience Inc
上場日Apr 10, 2014
最高経営責任者「CEO」Ms. Sabrina Martucci Johnson
従業員数21
証券種類Ordinary Share
決算期末Apr 10
本社所在地3655 Nobel Dr Ste 260
都市SAN DIEGO
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号92122-1050
電話番号18589267655
ウェブサイトhttps://www.darebioscience.com/
企業コードDARE
上場日Apr 10, 2014
最高経営責任者「CEO」Ms. Sabrina Martucci Johnson
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし